UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Differential monocyte responses to TLR ligands in children with autism spectrum disorders

Brain, behavior, and immunity, 2010-01, Vol.24 (1), p.64-71

2010

Volltextzugriff (PDF)

Altered gene expression and function of peripheral blood natural killer cells in children with autism

Brain, behavior, and immunity, 2009-01, Vol.23 (1), p.124-133

2009

Volltextzugriff (PDF)

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

Journal for immunotherapy of cancer, 2024-08, Vol.12 (8), p.e009475

2024

Volltextzugriff (PDF)

P104 Upregulation of both APRIL and BAFF in systemic lupus erythematosus suggests non-redundant roles, further revealed by potent dual inhibition with povetacicept (TACI vTD-Fc; ALPN-303)

Lupus science & medicine, 2024-03, Vol.11 (Suppl 1), p.A114-A115

2024

Volltextzugriff (PDF)

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Journal for immunotherapy of cancer, 2024-08, Vol.12 (8), p.e009474

2024

Volltextzugriff (PDF)

S276: POVETACICEPT (ALPN‐303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY‐RELATED DISEASES

HemaSphere, 2023-08, Vol.7 (S3), p.e3301055-n/a

2023

Volltextzugriff (PDF)

850 Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A891-A891

2021

Volltextzugriff (PDF)

Autoimmunity in autism

Current opinion in investigational drugs (London, England : 2000), 2009-05, Vol.10 (5), p.463

2009

Volltextzugriff (PDF)

Combinatorial peptide library methods for immunobiology research

Experimental Hematology, 2003, Vol.31 (1), p.11-30

2003

Volltextzugriff (PDF)

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist in Development for the Treatment of Autoimmune Cytopenias, Suppresses Disease in a Mouse Model of Autoimmune Hemolytic Anemia

Blood, 2023-11, Vol.142 (Supplement 1), p.6462-6462

2023

Volltextzugriff (PDF)

Synthesis and Screening of “One-Bead One-Compound” Combinatorial Peptide Libraries

Methods in Enzymology, 2003, Vol.369, p.298-322

2003

Volltextzugriff (PDF)

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

Clinical cancer research, 2019-09, Vol.25 (18), p.5493-5502

2019

Volltextzugriff (PDF)

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

Clinical cancer research, 2019-10, Vol.25 (19), p.5787-5798

2019

Volltextzugriff (PDF)

1342 Updated results from the RUBY-3 study of povetacicept, an enhanced dual BAFF/APRIL antagonist, in autoantibody-associated glomerulonephritis

Nephrology, dialysis, transplantation, 2024-05, Vol.39 (Supplement_1)

2024

Volltextzugriff (PDF)

Initial Report of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoimmune Cytopenias: The RUBY-4 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.5520-5520

2023

Volltextzugriff (PDF)

42273 Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Blistering Diseases

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB74-AB74

2023

Volltextzugriff (PDF)

4024 PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT FOR AUTOIMMUNE GLOMERULONEPHRITIDES

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

Blood, 2022-11, Vol.140 (Supplement 1), p.8401-8403

2022

Volltextzugriff (PDF)

Decreased transforming growth factor beta1 in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomes

Journal of neuroimmunology, 2008-11, Vol.204 (1), p.149-153

2008

Volltextzugriff (PDF)

Abstract 3606: Blockade of the PPARα metabolic checkpoint with TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3606-3606

2019

Volltextzugriff (PDF)

Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent (SA) or in combination in patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS2665-TPS2665

2019

Volltextzugriff (PDF)

WCN24-762 UPDATED RESULTS FROM THE RUBY-3 STUDY OF POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS

Kidney international reports, 2024-04, Vol.9 (4), p.S505-S505

2024

Volltextzugriff (PDF)

WCN24-756 POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS

Kidney international reports, 2024-04, Vol.9 (4), p.S141-S141

2024

Volltextzugriff (PDF)

A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.TPS200-TPS200

2018

Volltextzugriff (PDF)

Increased IgG4 levels in children with autism disorder

Brain, behavior, and immunity, 2009-03, Vol.23 (3), p.389-395

2009

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(45)
Dissertationen
(1)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Differential monocyte responses to TLR ligands in children with autism spectrum disorders

Altered gene expression and function of peripheral blood natural killer cells in children with autism

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

P104 Upregulation of both APRIL and BAFF in systemic lupus erythematosus suggests non-redundant roles, further revealed by potent dual inhibition with povetacicept (TACI vTD-Fc; ALPN-303)

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

S276: POVETACICEPT (ALPN‐303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY‐RELATED DISEASES

850 Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway

Autoimmunity in autism

Combinatorial peptide library methods for immunobiology research

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist in Development for the Treatment of Autoimmune Cytopenias, Suppresses Disease in a Mouse Model of Autoimmune Hemolytic Anemia

Synthesis and Screening of “One-Bead One-Compound” Combinatorial Peptide Libraries

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

1342 Updated results from the RUBY-3 study of povetacicept, an enhanced dual BAFF/APRIL antagonist, in autoantibody-associated glomerulonephritis

Initial Report of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoimmune Cytopenias: The RUBY-4 Study

42273 Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Blistering Diseases

4024 PHASE 1 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT FOR AUTOIMMUNE GLOMERULONEPHRITIDES

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

Decreased transforming growth factor beta1 in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomes

Abstract 3606: Blockade of the PPARα metabolic checkpoint with TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity

Phase 1/1b multicenter trial of TPST-1120, a peroxisome proliferator-activated receptor alpha (PPARα) antagonist as a single agent (SA) or in combination in patients with advanced solid tumors

WCN24-762 UPDATED RESULTS FROM THE RUBY-3 STUDY OF POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS

WCN24-756 POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS

A phase 2 trial of CRS-207 and pembrolizumab in adults with recurrence of metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinomas

Increased IgG4 levels in children with autism disorder

Suchergebnisse filtern